{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:28:32Z","timestamp":1771954112499,"version":"3.50.1"},"reference-count":540,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s43440-020-00152-9","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T13:04:23Z","timestamp":1597928663000},"page":"1446-1478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacological treatments of COVID-19"],"prefix":"10.1007","volume":"72","author":[{"given":"Adeleh","family":"Sahebnasagh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razieh","family":"Avan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Saghafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojataba","family":"Mojtahedzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsaneh","family":"Sadremomtaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Arasteh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asal","family":"Tanzifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Faramarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Negarandeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Safdari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Khataminia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Rezai Ghaleno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Habtemariam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-1857","authenticated-orcid":false,"given":"Amirhosein","family":"Khoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"152_CR1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270\u20133.","journal-title":"Nature"},{"key":"152_CR2","unstructured":"De Salazar PM et al. Early Release-Identifying Locations with Possible Undetected Imported Severe Acute Respiratory Syndrome Coronavirus 2 Cases by Using Importation Predictions."},{"key":"152_CR3","unstructured":"Organization WH. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. 2020; https:\/\/wwwwhoint\/emergencies\/diseases\/novel-coronavirus-2019\/technical-guidance\/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it."},{"key":"152_CR4","unstructured":"Organization WH. Coronavirus disease 2019 (COVID-19)-Situation report-45; 2020"},{"key":"152_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.07.937862","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya AE, Baker SC, Baric R,Groot RJd, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses-a statement of the Coronavirus Study Group. 2020. https:\/\/doi.org\/10.1101\/2020.02.07.937862.","journal-title":"Severe acute respiratory syndrome-related coronavirus: The species and its viruses-a statement of the Coronavirus Study Group."},{"issue":"6","key":"152_CR6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","volume":"24","author":"S Su","year":"2016","unstructured":"Su S, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490\u2013502.","journal-title":"Trends Microbiol"},{"issue":"5","key":"152_CR7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","volume":"15","author":"A Zumla","year":"2016","unstructured":"Zumla A, et al. Coronaviruses\u2014drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"152_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40779-019-0229-2","volume":"7","author":"Y-R Guo","year":"2020","unstructured":"Guo Y-R, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u2013an update on the status. Military Med Res. 2020;7(1):1\u201310.","journal-title":"Military Med Res"},{"issue":"3","key":"152_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181\u201392.","journal-title":"Nat Rev Microbiol"},{"key":"152_CR10","volume-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","author":"G Li","year":"2020","unstructured":"Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Berlin: Nature Publishing Group; 2020."},{"key":"152_CR11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"C Wu","year":"2020","unstructured":"Wu C, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020;10:766\u201388.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"152_CR12","unstructured":"Guan W.-J. et al. Clinical characteristics of coronavirus disease 2019 in China. New England J Med. 2020."},{"issue":"1\u20132","key":"152_CR13","first-page":"107","volume":"532","author":"H Dan","year":"2002","unstructured":"Dan H, Maureen G, Richard B. Quantitative mRNA expression proflling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002;532(1\u20132):107.","journal-title":"FEBS Lett"},{"key":"152_CR14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562\u20139.","journal-title":"Nat Microbiol"},{"key":"152_CR15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.","journal-title":"JAMA"},{"key":"152_CR16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","volume":"9","author":"L Lin","year":"2020","unstructured":"Lin L, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection\u2014\u2014a review of immune changes in patients with viral pneumonia. Emerg Microb Infect. 2020;9:727\u201332.","journal-title":"Emerg Microb Infect"},{"key":"152_CR17","doi-asserted-by":"crossref","first-page":"105948","DOI":"10.1016\/j.ijantimicag.2020.105948","volume":"55","author":"L-S Wang","year":"2020","unstructured":"Wang L-S, et al. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020;55:105948.","journal-title":"Int J Antimicrob Agents"},{"key":"152_CR18","doi-asserted-by":"crossref","first-page":"102523","DOI":"10.1016\/j.autrev.2020.102523","volume":"19","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, et al. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. 2020;19:102523.","journal-title":"Autoimmun Rev"},{"key":"152_CR19","doi-asserted-by":"publisher","unstructured":"Sahebnasagh, A. et al., Neutrophil Elastase Inhibitor (Sivelestat), may be a Promising Therapeutic Option for Management of Acute Lung Injury\/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in COVID-19. 2020; https:\/\/doi.org\/10.22541\/au.158981143.30930108.","DOI":"10.22541\/au.158981143.30930108"},{"key":"152_CR20","unstructured":"National Health Commission of the People\u2019s Republic of China. Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (version 6). 2020."},{"issue":"7477","key":"152_CR21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nature12711","volume":"503","author":"X-Y Ge","year":"2013","unstructured":"Ge X-Y, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535\u20138.","journal-title":"Nature"},{"issue":"6965","key":"152_CR22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450\u20134.","journal-title":"Nature"},{"issue":"11","key":"152_CR23","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","volume":"14","author":"AS Omrani","year":"2014","unstructured":"Omrani AS, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090\u20135.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"152_CR24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","volume":"92","author":"L Zhang","year":"2020","unstructured":"Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020;92(5):479\u201390.","journal-title":"J Med Virol"},{"key":"152_CR25","doi-asserted-by":"crossref","unstructured":"Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020.","DOI":"10.1128\/AAC.00399-20"},{"key":"152_CR26","doi-asserted-by":"crossref","unstructured":"Zhang Y et al. Current targeted therapeutics against COVID-19: based on first-line experience in china. Pharmacol Res. 2020; p. 104854.","DOI":"10.1016\/j.phrs.2020.104854"},{"key":"152_CR27","doi-asserted-by":"crossref","unstructured":"Khalili JS et al. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID\u201019. J Med Virol. 2020.","DOI":"10.1002\/jmv.25798"},{"key":"152_CR28","unstructured":"Khan S et al. The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options. J Clin Microbiol. 2020."},{"issue":"1","key":"152_CR29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3851\/IMP2792","volume":"20","author":"M Khalid","year":"2015","unstructured":"Khalid M, et al. Ribavirin and interferon-\u03b12b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. Antivir Ther. 2015;20(1):87\u201391.","journal-title":"Antivir Ther"},{"issue":"5","key":"152_CR30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","volume":"21","author":"UJ Kim","year":"2016","unstructured":"Kim UJ, et al. Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455\u20139.","journal-title":"Antivir Ther"},{"key":"152_CR31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijid.2013.12.003","volume":"20","author":"JA Al-Tawfiq","year":"2014","unstructured":"Al-Tawfiq JA, et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42\u20136.","journal-title":"Int J Infect Dis"},{"key":"152_CR32","unstructured":"Arabi YM et al. Effect of Ribavirin and Interferon on the Outcome of Critically Ill patients with MERS. In C63. viral respiratory infections. American Thoracic Society. 2017; p. A6067\u2013A6067."},{"key":"152_CR33","doi-asserted-by":"crossref","unstructured":"Zhou C et al. COVID-19 with spontaneous pneumomediastinum. Lancet Infect Dis. 2020.","DOI":"10.1016\/S1473-3099(20)30156-0"},{"issue":"5","key":"152_CR34","first-page":"e7995","volume":"12","author":"AA Alalwan","year":"2020","unstructured":"Alalwan AA, Taher A, Alaradi AH. A hemodialysis patient with severe COVID-19 pneumonia. Cureus. 2020;12(5):e7995.","journal-title":"Cureus."},{"key":"152_CR35","doi-asserted-by":"crossref","unstructured":"Wang R et al. COVID-19 in hemodialysis patients: a report of 5 cases. Am J Kidney Dis. 2020.","DOI":"10.1053\/j.ajkd.2020.03.009"},{"issue":"4","key":"152_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2020.0156","volume":"81","author":"F Wu","year":"2020","unstructured":"Wu F, et al. Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again. Br J Hosp Med. 2020;81(4):1\u20132.","journal-title":"Br J Hosp Med"},{"key":"152_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-019-4717-5","volume":"20","author":"P Zhang","year":"2020","unstructured":"Zhang P, et al. The novel coronavirus (COVID-19) pneumonia with negative detection of viral ribonucleic acid from nasopharyngeal swabs: a case report. BMC Infect Dis. 2020;20:1\u20137.","journal-title":"BMC Infect Dis"},{"key":"152_CR38","unstructured":"Hung IF-N, et al. Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet. 2020."},{"issue":"9","key":"152_CR39","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/CM9.0000000000000790","volume":"133","author":"Y-M Zeng","year":"2020","unstructured":"Zeng Y-M, et al. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir\/ritonavir plus interferon-alpha, and ribavirin plus lopinavir\/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol. Chin Med J. 2020;133(9):1132\u20134.","journal-title":"Chin Med J"},{"issue":"1","key":"152_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijp.IJP_119_20","volume":"52","author":"P Sarma","year":"2020","unstructured":"Sarma P, et al. Therapeutic options for the treatment of 2019-novel coronavirus: an evidence-based approach. Indian J Pharmacol. 2020;52(1):1.","journal-title":"Indian J Pharmacol"},{"key":"152_CR41","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis."},{"key":"152_CR42","unstructured":"Control CFD. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). 2020."},{"issue":"2","key":"152_CR43","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini ML, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221\u2013e318.","journal-title":"MBio"},{"issue":"396","key":"152_CR44","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan TP, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Trans Med. 2017;9(396):eaal3653.","journal-title":"Sci Trans Med"},{"key":"152_CR45","doi-asserted-by":"crossref","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown AJ, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.","journal-title":"Antiviral Res"},{"issue":"5","key":"152_CR46","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cbic.202000047","volume":"21","author":"JS Morse","year":"2020","unstructured":"Morse JS, Lalonde T, Xu S, Liu W. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730\u20138. https:\/\/doi.org\/10.1002\/cbic.202000047.","journal-title":"Chembiochem."},{"key":"152_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv130.02","author":"T Warren","year":"2015","unstructured":"Warren T, et al. Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides complete therapeutic protection against the development of Ebola virus disease (EVD) in infected non-human primates in Open Forum Infectious Diseases. Infect Dis Soc Am. 2015. https:\/\/doi.org\/10.1093\/ofid\/ofv130.02.","journal-title":"Infect Dis Soc Am"},{"issue":"SPL1","key":"152_CR48","first-page":"1","volume":"11","author":"V Yethindra","year":"2020","unstructured":"Yethindra V. Role of GS-5734 (Remdesivir) in inhibiting SARS-CoV and MERS-CoV: the expected role of GS-5734 (Remdesivir) in COVID-19 (2019-nCoV)-VYTR hypothesis. Int J Res Pharmaceutical Sci. 2020;11(SPL1):1\u20136.","journal-title":"Int J Res Pharmaceutical Sci"},{"issue":"3","key":"152_CR49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269\u201371.","journal-title":"Cell Res"},{"issue":"1","key":"152_CR50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Therapeutics. 2020;14(1):58\u201360.","journal-title":"Drug Discov Therapeutics"},{"key":"152_CR51","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","volume":"34","author":"JA Al-Tawfiq","year":"2020","unstructured":"Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020;34:101615.","journal-title":"Travel Med Infect Dis"},{"key":"152_CR52","doi-asserted-by":"crossref","unstructured":"Holshue ML, et al. First case of 2019 novel coronavirus in the United States. New Engl J Med. 2020.","DOI":"10.1056\/NEJMoa2001191"},{"issue":"1","key":"152_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, et al. comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1\u201314.","journal-title":"Nat Commun"},{"key":"152_CR54","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04252664. 2020; Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04252664."},{"key":"152_CR55","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04257656. 2020; Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04257656."},{"key":"152_CR56","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04345276, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04345276?term= NCT04345276&cond=COVID-19&draw=2&rank=1."},{"key":"152_CR57","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04315948. 2020; Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315948."},{"key":"152_CR58","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04292899. 2020; Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04292899."},{"key":"152_CR59","unstructured":"Goldman JD, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. New Engl J Med."},{"key":"152_CR60","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Therapeutics. 2020;209:107512.","journal-title":"Pharmacol Therapeutics"},{"issue":"3","key":"152_CR61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","volume":"82","author":"Y Furuta","year":"2009","unstructured":"Furuta Y, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82(3):95\u2013102.","journal-title":"Antiviral Res"},{"key":"152_CR62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.antiviral.2018.10.026","volume":"160","author":"NAS Guerrero","year":"2018","unstructured":"Guerrero NAS, et al. Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice. Antiviral Res. 2018;160:137\u201342.","journal-title":"Antiviral Res"},{"issue":"4","key":"152_CR63","doi-asserted-by":"crossref","first-page":"e2790","DOI":"10.1371\/journal.pntd.0002790","volume":"8","author":"AL Caroline","year":"2014","unstructured":"Caroline AL, et al. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLoS Neglected Tropic Dis. 2014;8(4):e2790.","journal-title":"PLoS Neglected Tropic Dis"},{"issue":"2","key":"152_CR64","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","volume":"32","author":"FG Hayden","year":"2019","unstructured":"Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019;32(2):176.","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"152_CR65","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbrc.2012.07.034","volume":"424","author":"J Rocha-Pereira","year":"2012","unstructured":"Rocha-Pereira J, et al. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun. 2012;424(4):777\u201380.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"152_CR66","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","volume":"15","author":"F Mentr\u00e9","year":"2015","unstructured":"Mentr\u00e9 F, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015;15(2):150\u20131.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"152_CR67","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","volume":"24","author":"K Rosenke","year":"2018","unstructured":"Rosenke K, et al. Use of favipiravir to treat Lassa virus infection in macaques. Emerg Infect Dis. 2018;24(9):1696.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"152_CR68","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","volume":"57","author":"D Safronetz","year":"2013","unstructured":"Safronetz D, et al. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013;57(10):4673\u201380.","journal-title":"Antimicrob Agents Chemother"},{"key":"152_CR69","doi-asserted-by":"crossref","unstructured":"Cai Q, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020.","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"152_CR70","doi-asserted-by":"crossref","unstructured":"Chen C, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv, 2020.","DOI":"10.1101\/2020.03.17.20037432"},{"issue":"1","key":"152_CR71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"H Lu","year":"2020","unstructured":"Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69\u201371.","journal-title":"Biosci Trends"},{"key":"152_CR72","first-page":"187","volume":"6","author":"A Kamali","year":"2013","unstructured":"Kamali A, Holodniy M. Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infect Drug Resist. 2013;6:187.","journal-title":"Infect Drug Resist"},{"key":"152_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa105","author":"EK McCreary","year":"2020","unstructured":"McCreary EK, Pogue JM. COVID-19 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020. https:\/\/doi.org\/10.1093\/ofid\/ofaa105.","journal-title":"Open Forum Infect Dis"},{"issue":"10223","key":"152_CR74","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507\u201313.","journal-title":"The Lancet"},{"key":"152_CR75","doi-asserted-by":"crossref","unstructured":"Xu X-W, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020; 368.","DOI":"10.1136\/bmj.m606"},{"issue":"15","key":"152_CR76","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1097\/00002030-200210180-00015","volume":"16","author":"M Boffito","year":"2002","unstructured":"Boffito M, et al. Clinical use of lopinavir\/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. Aids. 2002;16(15):2081\u20133.","journal-title":"Aids"},{"key":"152_CR77","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","volume":"92","author":"TT Yao","year":"2020","unstructured":"Yao TT, et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus\u2014a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92:556\u201363.","journal-title":"J Med Virol"},{"issue":"3","key":"152_CR78","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/1995-7645.277815","volume":"13","author":"S Yasri","year":"2020","unstructured":"Yasri S, Wiwanitkit V. Dose prediction of lopinavir\/ritonavir based on mathematic modeling for 2019-novel coronavirus (2019-nCoV) infection. Asian Pacific J Trop Med. 2020;13(3):1\u20132. https:\/\/doi.org\/10.4103\/1995-7645.277815.","journal-title":"Asian Pacific J Trop Med"},{"issue":"6","key":"152_CR79","first-page":"399","volume":"9","author":"T Que","year":"2003","unstructured":"Que T, Wong V, Yuen K. Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399\u2013406.","journal-title":"Hong Kong Med J"},{"issue":"3","key":"152_CR80","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3947\/ic.2015.47.3.212","volume":"47","author":"YP Chong","year":"2015","unstructured":"Chong YP, et al. Antiviral treatment guidelines for Middle East respiratory syndrome. Infect Chemother. 2015;47(3):212\u201322.","journal-title":"Infect Chemother"},{"key":"152_CR81","doi-asserted-by":"crossref","unstructured":"Mallat J, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: a retrospective study. medRxiv. 2020.","DOI":"10.1101\/2020.04.27.20082180"},{"issue":"6","key":"152_CR82","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.apjtm.2017.06.012","volume":"10","author":"S Wiwanitkit","year":"2017","unstructured":"Wiwanitkit S, Wiwanitkit V. Doubled dosage of sofosbuvir is expected for inhibiting Zika virus infection. Asian Pacific J Trop Med. 2017;10(6):612\u20133.","journal-title":"Asian Pacific J Trop Med"},{"key":"152_CR83","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","author":"VM Corman","year":"2020","unstructured":"Corman VM, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.3.2000045.","journal-title":"Eurosurveillance"},{"issue":"3","key":"152_CR84","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41579-020-0332-0","volume":"18","author":"A Du Toit","year":"2020","unstructured":"Du Toit A. Outbreak of a novel coronavirus. Nat Rev Microbiol. 2020;18(3):123\u2013123.","journal-title":"Nat Rev Microbiol"},{"key":"152_CR85","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000044","author":"P Wu","year":"2020","unstructured":"Wu P, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Eurosurveillance. 2020. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.3.2000044.","journal-title":"Eurosurveillance"},{"key":"152_CR86","volume-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","author":"C Liu","year":"2020","unstructured":"Liu C, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. Washington: ACS Publications; 2020."},{"key":"152_CR87","first-page":"400","volume":"19","author":"JT Ortega","year":"2020","unstructured":"Ortega JT, et al. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: the main protease as molecular target. EXCLI J. 2020;19:400.","journal-title":"EXCLI J"},{"key":"152_CR88","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","volume":"14","author":"Z Wang","year":"2020","unstructured":"Wang Z, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14:64\u20138.","journal-title":"Biosci Trends"},{"issue":"3","key":"152_CR89","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"C Chu","year":"2004","unstructured":"Chu C, et al. Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252\u20136.","journal-title":"Thorax"},{"key":"152_CR90","doi-asserted-by":"publisher","unstructured":"Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI-P, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel Coronavirus (2019-ncoV): a systematic review. J Clin Med. 2020;9(3):623. https:\/\/doi.org\/10.3390\/jcm9030623.","DOI":"10.3390\/jcm9030623"},{"key":"152_CR91","doi-asserted-by":"crossref","unstructured":"Lim J, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020; 35(6).","DOI":"10.3346\/jkms.2020.35.e79"},{"key":"152_CR92","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","volume":"323","author":"BE Young","year":"2020","unstructured":"Young BE, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323:1488.","journal-title":"JAMA"},{"key":"152_CR93","unstructured":"Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment."},{"key":"152_CR94","unstructured":"Cao B, et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. New Engl J Med. 2020."},{"key":"152_CR95","doi-asserted-by":"crossref","unstructured":"Baden LR, Rubin EJ. Covid-19\u2014the search for effective therapy. Mass Med Soc. 2020.","DOI":"10.1056\/NEJMe2005477"},{"key":"152_CR96","unstructured":"https:\/\/www.szdsyy.com\/News\/0a6c1e58-e3d0-4cd1. 22 Feb 2020."},{"key":"152_CR97","unstructured":"Lopinavir and ritonavir. 6 Feb 2020."},{"issue":"6","key":"152_CR98","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2165\/00003495-200060060-00009","volume":"60","author":"M Hurst","year":"2000","unstructured":"Hurst M, Faulds D. Lopinavir. Drugs. 2000;60(6):1371\u20139.","journal-title":"Drugs"},{"issue":"6","key":"152_CR99","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2014.07.026","volume":"44","author":"N Spanakis","year":"2014","unstructured":"Spanakis N, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents. 2014;44(6):528\u201332.","journal-title":"Int J Antimicrob Agents"},{"key":"152_CR100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","volume":"21","author":"UJ Kim","year":"2016","unstructured":"Kim UJ, et al. Case report Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-\u03b1 for Middle East respiratory syndrome. Antiviral Ther. 2016;21:455\u20139.","journal-title":"Antiviral Ther"},{"key":"152_CR101","unstructured":"Arbidol and darunavir can effectively inhibit coronavirus. 21 Feb 2020."},{"key":"152_CR102","unstructured":"Mak E. Coronavirus outbreak pushes chinese biotech stocks higher despite market downturn. 7 Feb 2020."},{"issue":"6","key":"152_CR103","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/aid.2018.0178","volume":"35","author":"JR Santos","year":"2019","unstructured":"Santos JR, et al. Simplification of antiretroviral treatment from darunavir\/ritonavir monotherapy to darunavir\/cobicistat monotherapy: effectiveness and safety in routine clinical practice. AIDS Res Hum Retroviruses. 2019;35(6):513\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"152_CR104","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/clpt.2009.228","volume":"87","author":"A Mathias","year":"2010","unstructured":"Mathias A, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87(3):322\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"152_CR105","unstructured":"Hu F, Jiang J, Yin P. Prediction of potential commercially inhibitors against SARS-CoV-2 by multi-task deep model. arXiv preprint. 2020; arXiv:2003.00728."},{"key":"152_CR106","doi-asserted-by":"crossref","unstructured":"Talluri S. Virtual High Throughput Screening Based Prediction of Potential Drugs for COVID-19. 2020.","DOI":"10.20944\/preprints202002.0418.v1"},{"key":"152_CR107","doi-asserted-by":"crossref","unstructured":"Omotuyi OI, et al. Darunavir Disrupts Critical Nodes in Metastable 2019-nCoV-RBD\/ACE-2 Complex. 2020.","DOI":"10.20944\/preprints202003.0125.v1"},{"issue":"5","key":"152_CR108","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/jm400164c","volume":"57","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, et al. Discovery of danoprevir (ITMN-191\/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3\/4A protease. J Med Chem. 2014;57(5):1753\u201369.","journal-title":"J Med Chem"},{"key":"152_CR109","unstructured":"Wieslaw M. Kazmierski, Richard L. Jarvest, Jacob J. Plattner, Xianfeng Li. Linear and macrocyclic hepatitis C virus protease inhibitors. In: Levin JI editor. Macrocycles in drug discovery. vol 40.\u00a0Royal Society of Chemistry; 2015. p. 247."},{"key":"152_CR110","first-page":"E1","volume":"307","author":"A Zhavoronkov","year":"2020","unstructured":"Zhavoronkov A, et al. Potential COVID-2019 3C-like protease inhibitors designed using generative deep learning approaches. Insilico Med Hong Kong Ltd A. 2020;307:E1.","journal-title":"Insilico Med Hong Kong Ltd A"},{"issue":"2","key":"152_CR111","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0014-5793(89)80109-7","volume":"243","author":"AE Gorbalenya","year":"1989","unstructured":"Gorbalenya AE, et al. Cysteine proteases of positive strand RNA viruses and chymotrypsin-like serine protease. A distinct protein superfamily with a common structural fold. FEBS Lett. 1989;243(2):103\u201314.","journal-title":"FEBS Lett."},{"issue":"13","key":"152_CR112","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","volume":"21","author":"K Anand","year":"2002","unstructured":"Anand K, et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. Embo J. 2002;21(13):3213\u201324.","journal-title":"Embo J"},{"key":"152_CR113","unstructured":"Hosseini FS, Amanlou M. Simeprevir, potential candidate to repurpose for coronavirus infection: virtual screening and molecular docking study."},{"key":"152_CR114","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coph.2016.07.015","volume":"30","author":"JA McCauley","year":"2016","unstructured":"McCauley JA, Rudd MT. Hepatitis C virus NS3\/4a protease inhibitors. Curr Opin Pharmacol. 2016;30:84\u201392.","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"152_CR115","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40265-018-0960-0","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A, Keam SJ. Danoprevir: first global approval. Drugs. 2018;78(12):1271\u20136.","journal-title":"Drugs"},{"issue":"2","key":"152_CR116","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.01515-13","volume":"58","author":"EJ Gane","year":"2014","unstructured":"Gane EJ, et al. Efficacy and safety of danoprevir-ritonavir plus peginterferon Alfa-2a\u2013ribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob Agents Chemother. 2014;58(2):1136\u201345.","journal-title":"Antimicrob Agents Chemother"},{"key":"152_CR117","doi-asserted-by":"crossref","unstructured":"Chen H., et al. First clinical study using HCV protease inhibitor danoprevir to treat naive and experienced COVID-19 Patients. MedRxiv. 2020.","DOI":"10.1101\/2020.03.22.20034041"},{"key":"152_CR118","unstructured":"Choi J, Horner KA, Carnevale K. Atazanavir, in StatPearls. StatPearls Publishing. 2019."},{"issue":"13","key":"152_CR119","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","volume":"21","author":"K Anand","year":"2002","unstructured":"Anand K, et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra \u03b1-helical domain. EMBO J. 2002;21(13):3213\u201324.","journal-title":"EMBO J"},{"issue":"3","key":"152_CR120","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5114\/aoms.2020.94567","volume":"16","author":"JF Borgio","year":"2020","unstructured":"Borgio JF, et al. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2. Arch Med Sci. 2020;16(3):508.","journal-title":"Arch Med Sci"},{"key":"152_CR121","doi-asserted-by":"crossref","unstructured":"Beck BR, et al. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020.","DOI":"10.1101\/2020.01.31.929547"},{"issue":"3","key":"152_CR122","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2215\/CJN.02240218","volume":"14","author":"MG Atta","year":"2019","unstructured":"Atta MG, De Seigneux S, Lucas GM. Clinical pharmacology in HIV therapy. Clin J Am Soc Nephrol. 2019;14(3):435\u201344.","journal-title":"Clin J Am Soc Nephrol"},{"key":"152_CR123","unstructured":"Contini A. Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins."},{"key":"152_CR124","doi-asserted-by":"crossref","unstructured":"Shaghaghi,N. Molecular docking study of novel COVID-19 protease with low risk terpenoides compounds of plants. ChemRxiv. 2020.","DOI":"10.26434\/chemrxiv.11935722.v1"},{"key":"152_CR125","doi-asserted-by":"crossref","unstructured":"Bulduk I, Taktak F. Isolation and characterization of antitumor alkaloid from poppy capsules (papaver somniferum). J Chem. 2012; 2013.","DOI":"10.1155\/2013\/493870"},{"issue":"1","key":"152_CR126","first-page":"101","volume":"11","author":"M Heydari","year":"2013","unstructured":"Heydari M, Hashem Hashempur M, Zargaran A. Medicinal aspects of opium as described in Avicenna\u2019s Canon of Medicine. Acta medico-historica Adriatica. 2013;11(1):101\u201312.","journal-title":"Acta medico-historica Adriatica"},{"key":"152_CR127","doi-asserted-by":"crossref","unstructured":"Kumar D, et al. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures. J Biomol Struct Dyn. 2020; 1\u201314.","DOI":"10.1080\/07391102.2020.1752310"},{"key":"152_CR128","doi-asserted-by":"crossref","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","volume":"177","author":"F Touret","year":"2020","unstructured":"Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177:104762.","journal-title":"Antiviral Res"},{"key":"152_CR129","doi-asserted-by":"crossref","first-page":"109815","DOI":"10.1016\/j.mehy.2020.109815","volume":"142","author":"R Derwand","year":"2020","unstructured":"Derwand R, Scholz M. Does zinc supplementation enhance the clinical efficacy of chloroquine\/hydroxychloroquine to win todays battle against COVID-19? Med Hypotheses. 2020;142:109815.","journal-title":"Med Hypotheses"},{"key":"152_CR130","doi-asserted-by":"crossref","unstructured":"Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020.","DOI":"10.1093\/jac\/dkaa114"},{"key":"152_CR131","doi-asserted-by":"crossref","unstructured":"Yao X, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020.","DOI":"10.1093\/cid\/ciaa237"},{"key":"152_CR132","doi-asserted-by":"crossref","first-page":"117775","DOI":"10.1016\/j.lfs.2020.117775","volume":"254","author":"VM Patil","year":"2020","unstructured":"Patil VM, Singhal S, Masand N. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. Life Sci. 2020;254:117775.","journal-title":"Life Sci"},{"key":"152_CR133","doi-asserted-by":"crossref","unstructured":"Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020.","DOI":"10.5582\/bst.2020.01047"},{"key":"152_CR134","unstructured":"[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(3): 185\u2013188."},{"issue":"4","key":"152_CR135","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","volume":"3","author":"MGS Borba","year":"2020","unstructured":"Borba MGS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857\u2013e208857208857.","journal-title":"JAMA Netw Open"},{"key":"152_CR136","doi-asserted-by":"crossref","unstructured":"Chang R, Sun W-Z. Repositioning Chloroquine as Ideal Antiviral Prophylactic against COVID-19-Time is Now. 2020.","DOI":"10.20944\/preprints202003.0279.v1"},{"key":"152_CR137","doi-asserted-by":"crossref","unstructured":"Shah S, et al. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease\u201019 (COVID\u201019). Int J Rheumatic Dis. 2020.","DOI":"10.1111\/1756-185X.13842"},{"key":"152_CR138","unstructured":"de Novales FJM, et al. Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study. 2020."},{"key":"152_CR139","doi-asserted-by":"crossref","unstructured":"Chen Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv 2020.","DOI":"10.1101\/2020.03.22.20040758"},{"key":"152_CR140","unstructured":"Mahevas M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medrxiv, 2020."},{"key":"152_CR141","doi-asserted-by":"crossref","unstructured":"Gautret P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; p. 105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"152_CR142","volume-title":"Treatment considerations for COVID-19: a critical review of the evidence (or Lack Thereof) in Mayo clinic proceedings","author":"P Vijayvargiya","year":"2020","unstructured":"Vijayvargiya P, et al. Treatment considerations for COVID-19: a critical review of the evidence (or Lack Thereof) in Mayo clinic proceedings. Amsterdam: Elsevier; 2020."},{"key":"152_CR143","doi-asserted-by":"crossref","unstructured":"Gautret P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020; p. 101663.","DOI":"10.1016\/j.tmaid.2020.101663"},{"key":"152_CR144","doi-asserted-by":"crossref","unstructured":"Gevers S, et al. Safety considerations of chloroquine and hydroxychloroquine in treatment of COVID-19. Clin Microbiol Infecti. 2020.","DOI":"10.1016\/j.cmi.2020.05.006"},{"issue":"10","key":"152_CR145","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"Y Boriskin","year":"2008","unstructured":"Boriskin Y, et al. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15(10):997\u20131005.","journal-title":"Curr Med Chem"},{"key":"152_CR146","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","volume":"107","author":"J Blaising","year":"2014","unstructured":"Blaising J, Polyak SJ, P\u00e9cheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84\u201394.","journal-title":"Antiviral Res"},{"issue":"4","key":"152_CR147","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/v10040184","volume":"10","author":"J Haviernik","year":"2018","unstructured":"Haviernik J, et al. Arbidol (Umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses. 2018;10(4):184.","journal-title":"Viruses"},{"issue":"4","key":"152_CR148","first-page":"9","volume":"53","author":"R Khamitov","year":"2008","unstructured":"Khamitov R, et al. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol. 2008;53(4):9\u201313.","journal-title":"Vopr Virusol"},{"key":"152_CR149","unstructured":"Notice on printing and distributing the diagnosis and treatment plan of COVID- 19 (trial version 6). National Health Commission of the People\u2019s Republic of China. 2020."},{"key":"152_CR150","doi-asserted-by":"crossref","unstructured":"Deng L, et al. Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020.","DOI":"10.1016\/j.jinf.2020.03.002"},{"key":"152_CR151","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243\u201352.","journal-title":"N Engl J Med"},{"issue":"4","key":"152_CR152","first-page":"694","volume":"37","author":"EHS Choy","year":"2019","unstructured":"Choy EHS, et al. The effect of JAK1\/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol. 2019;37(4):694\u201370.","journal-title":"Clin Exp Rheumatol."},{"issue":"10223","key":"152_CR153","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England). 2020;395(10223):e30.","journal-title":"Lancet (London, England)."},{"key":"152_CR154","doi-asserted-by":"crossref","unstructured":"Favalli EG, et al. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis 2020.","DOI":"10.1016\/S1473-3099(20)30262-0"},{"key":"152_CR155","doi-asserted-by":"crossref","unstructured":"Cantini F, et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020.","DOI":"10.1016\/j.jinf.2020.04.017"},{"key":"152_CR156","unstructured":"Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nature Publishing Group."},{"issue":"2","key":"152_CR157","first-page":"147","volume":"134","author":"S Albeituni","year":"2019","unstructured":"Albeituni S, et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood J Am Soc Hematol. 2019;134(2):147\u201359.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"152_CR158","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12955-019-1121-1","volume":"17","author":"RA Mesa","year":"2019","unstructured":"Mesa RA, et al. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health Quality Life Outcomes. 2019;17(1):61.","journal-title":"Health Quality Life Outcomes"},{"key":"152_CR159","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/JBM.S177692","volume":"10","author":"S Cingam","year":"2019","unstructured":"Cingam S, et al. Ruxolitinib in the treatment of polycythemia Vera: an update on health-related quality of life and patient-reported outcomes. J Blood Med. 2019;10:381.","journal-title":"J Blood Med"},{"issue":"4","key":"152_CR160","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400\u20132.","journal-title":"Lancet Infect Dis"},{"key":"152_CR161","doi-asserted-by":"crossref","unstructured":"Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. 2017.","DOI":"10.1186\/s13054-017-1882-z"},{"key":"152_CR162","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586\u201390.","journal-title":"Intensive Care Med"},{"key":"152_CR163","doi-asserted-by":"crossref","first-page":"117955061882193","DOI":"10.1177\/1179550618821930","volume":"12","author":"F Scaglione","year":"2019","unstructured":"Scaglione F, Petrini O. Mucoactive agents in the therapy of upper respiratory airways infections: fair to describe them just as mucoactive? Clin Med Insights Ear Nose Throat. 2019;12:1179550618821930.","journal-title":"Clin Med Insights Ear Nose Throat"},{"key":"152_CR164","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40248-017-0088-1","volume":"12","author":"A Zanasi","year":"2017","unstructured":"Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip Respir Med. 2017;12:7.","journal-title":"Multidiscip Respir Med"},{"key":"152_CR165","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-319-75474-1_11","volume-title":"Activation of viruses by host proteases","author":"T Steinmetzer","year":"2018","unstructured":"Steinmetzer T, Hardes K. The antiviral potential of host protease inhibitors. In: B\u00f6ttcher-Friebertsh\u00e4user E, Garten W, Klenk HD, editors. Activation of viruses by host proteases. Cham: Springer International Publishing; 2018. p. 279\u2013325."},{"issue":"3","key":"152_CR166","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.drudis.2019.01.018","volume":"24","author":"C-C Li","year":"2019","unstructured":"Li C-C, Wang X-J, Wang H-CR. Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discovery Today. 2019;24(3):726\u201336.","journal-title":"Drug Discovery Today"},{"key":"152_CR167","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2017.03.018","volume":"24","author":"M Laporte","year":"2017","unstructured":"Laporte M, Naesens L. Airway proteases: an emerging drug target for influenza and other respiratory virus infections. Curr Opin Virol. 2017;24:16\u201324.","journal-title":"Curr Opin Virol"},{"key":"152_CR168","doi-asserted-by":"crossref","unstructured":"Chen Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020.","DOI":"10.1016\/j.bbrc.2020.02.071"},{"key":"152_CR169","doi-asserted-by":"crossref","unstructured":"Sun J, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020.","DOI":"10.1016\/j.molmed.2020.02.008"},{"key":"152_CR170","doi-asserted-by":"crossref","unstructured":"Li C-C, Wang X-J, Wang H-CR. Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discovery Today. 2019.","DOI":"10.1016\/j.drudis.2019.01.018"},{"key":"152_CR171","doi-asserted-by":"crossref","unstructured":"Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discovery Today. 2020.","DOI":"10.1016\/j.drudis.2020.01.015"},{"issue":"9","key":"152_CR172","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/JVI.02472-07","volume":"82","author":"K Narayanan","year":"2008","unstructured":"Narayanan K, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008;82(9):4471\u20139.","journal-title":"J Virol"},{"issue":"34","key":"152_CR173","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0603144103","volume":"103","author":"W Kamitani","year":"2006","unstructured":"Kamitani W, et al. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc Natl Acad Sci. 2006;103(34):12885\u201390.","journal-title":"Proc Natl Acad Sci"},{"issue":"24","key":"152_CR174","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1001\/jama.290.24.3222","volume":"290","author":"MR Loutfy","year":"2003","unstructured":"Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Jama. 2003;290(24):3222\u20138.","journal-title":"Jama."},{"key":"152_CR175","unstructured":"Lokugamage KG, et al. SARS-CoV-2 sensitive to type I interferon pretreatment. bioRxiv. 2020."},{"key":"152_CR176","unstructured":"Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia, The 6th edn. 23 Feb 2020."},{"key":"152_CR177","doi-asserted-by":"crossref","unstructured":"Xu Z, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020.","DOI":"10.1016\/S2213-2600(20)30076-X"},{"key":"152_CR178","doi-asserted-by":"crossref","unstructured":"Han W, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020.","DOI":"10.1002\/jmv.25711"},{"key":"152_CR179","doi-asserted-by":"crossref","unstructured":"Song Y, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut. 2020.","DOI":"10.1136\/gutjnl-2020-320891"},{"issue":"5","key":"152_CR180","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4103\/ijo.IJO_639_20","volume":"68","author":"R Shetty","year":"2020","unstructured":"Shetty R, et al. Therapeutic opportunities to manage COVID-19\/SARS-CoV-2 infection: present and future. Indian J Ophthalmol. 2020;68(5):693.","journal-title":"Indian J Ophthalmol"},{"key":"152_CR181","doi-asserted-by":"crossref","unstructured":"Nile SH, et al. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020.","DOI":"10.1016\/j.cytogfr.2020.05.002"},{"key":"152_CR182","doi-asserted-by":"crossref","unstructured":"Estebanez M, et al. Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study. medRxiv. 2020.","DOI":"10.1101\/2020.05.15.20084293"},{"issue":"1","key":"152_CR183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-019-0370-3","volume":"10","author":"K-S Yuen","year":"2020","unstructured":"Yuen K-S, et al. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10(1):1\u20135.","journal-title":"Cell Biosci"},{"issue":"4","key":"152_CR184","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbrc.2004.11.128","volume":"326","author":"B Morgenstern","year":"2005","unstructured":"Morgenstern B, et al. Ribavirin and interferon-\u03b2 synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326(4):905\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"152_CR185","doi-asserted-by":"crossref","unstructured":"Dattola V, et al. Relationship between interferon beta-1A administration and intracranial vascular tone regulation in patients with relapsing-remitting multiple sclerosis: a pilot study. BioMed Res Int. 2017; 2017.","DOI":"10.1155\/2017\/5421416"},{"issue":"1","key":"152_CR186","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1189\/jlb.1212631","volume":"94","author":"MK Callahan","year":"2013","unstructured":"Callahan MK, Wolchok JD. At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukocyte Biol. 2013;94(1):41\u201353.","journal-title":"J Leukocyte Biol"},{"issue":"1","key":"152_CR187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0379-6","volume":"10","author":"B Liu","year":"2017","unstructured":"Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol. 2017;10(1):1\u20138.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"152_CR188","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1189\/jlb.0110037","volume":"88","author":"P Brahmamdam","year":"2010","unstructured":"Brahmamdam P, et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88(2):233\u201340.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"152_CR189","doi-asserted-by":"crossref","first-page":"219","DOI":"10.6026\/97320630016219","volume":"16","author":"F Chiappelli","year":"2020","unstructured":"Chiappelli F, Khakshooy A, Greenberg G. CoViD-19 immunopathology and immunotherapy. Bioinformation. 2020;16(3):219\u201322.","journal-title":"Bioinformation"},{"key":"152_CR190","doi-asserted-by":"crossref","unstructured":"Weber J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017.","DOI":"10.1200\/JCO.2015.66.1389"},{"issue":"2","key":"152_CR191","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003495-198020020-00001","volume":"20","author":"GR Renoux","year":"1980","unstructured":"Renoux GR. The general immunopharmacology of levamisole. Drugs. 1980;20(2):89\u201399.","journal-title":"Drugs"},{"issue":"3","key":"152_CR192","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1172\/JCI111069","volume":"72","author":"M Joffe","year":"1983","unstructured":"Joffe M, Sukha N, Rabson A. Lymphocyte subsets in measles. Depressed helper\/inducer subpopulation reversed by in vitro treatment with levamisole and ascorbic acid. J Clin Investig. 1983;72(3):971\u201380.","journal-title":"J Clin Investig"},{"issue":"3","key":"152_CR193","first-page":"493","volume":"25","author":"M Rosenthal","year":"1976","unstructured":"Rosenthal M, Trabert U, M\u00fcller W. The effect of Levamisole on peripheral blood lymphocyte subpopulations in patients with rheumatoid arthritis and ankylosing spondylitis. Clin Exp Immunol. 1976;25(3):493.","journal-title":"Clin Exp Immunol"},{"key":"152_CR194","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200516047468N1, Available From: https:\/\/www.irct.ir\/trial\/46561"},{"key":"152_CR195","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20190917044805N2, Available From: https:\/\/www.irct.ir\/trial\/46561"},{"issue":"1","key":"152_CR196","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/22221751.2020.1741327","volume":"9","author":"T Li","year":"2020","unstructured":"Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microb Infect. 2020;9(1):687\u201390.","journal-title":"Emerg Microb Infect"},{"issue":"6","key":"152_CR197","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/v4061011","volume":"4","author":"S Belouzard","year":"2012","unstructured":"Belouzard S, et al. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011\u201333.","journal-title":"Viruses"},{"issue":"9","key":"152_CR198","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","volume":"3","author":"LJ Stockman","year":"2006","unstructured":"Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.","journal-title":"PLoS Med"},{"issue":"7","key":"152_CR199","first-page":"453","volume":"42","author":"W Wu","year":"2003","unstructured":"Wu W, et al. Clinical features of 96 patients with severe acute respiratory syndrome from a hospital outbreak. Zhonghua nei ke za zhi. 2003;42(7):453\u20137.","journal-title":"Zhonghua nei ke za zhi"},{"issue":"8","key":"152_CR200","first-page":"574","volume":"41","author":"Z Li","year":"2003","unstructured":"Li Z, et al. Clinical analysis of pediatric SARS cases in Beijing. Zhonghua er ke za zhi= Chin J Pediatrics. 2003;41(8):574\u20137.","journal-title":"Zhonghua er ke za zhi= Chin J Pediatrics"},{"issue":"4","key":"152_CR201","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41591-020-0817-4","volume":"26","author":"Y Xu","year":"2020","unstructured":"Xu Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502\u20135.","journal-title":"Nat Med"},{"issue":"17","key":"152_CR202","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci. 2020;117(17):9490\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"18","key":"152_CR203","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","volume":"75","author":"E Driggin","year":"2020","unstructured":"Driggin E, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am College Cardiol. 2020;75(18):2352\u201371.","journal-title":"J Am College Cardiol"},{"key":"152_CR204","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S10101","volume":"6","author":"E Portaccio","year":"2011","unstructured":"Portaccio E. Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evidence. 2011;6:13.","journal-title":"Core Evidence"},{"key":"152_CR205","doi-asserted-by":"crossref","unstructured":"Sato K, et al. Disease exacerbation after the cessation of fingolimod treatment in Japanese patients with multiple sclerosis. Intern Med. 2018; p. 0793\u201318.","DOI":"10.2169\/internalmedicine.0793-18"},{"key":"152_CR206","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04268537, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04268537?term=NCT04268537&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR207","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.2147\/JPR.S213112","volume":"12","author":"H Xu","year":"2019","unstructured":"Xu H, et al. Systemic injection of thalidomide prevent and attenuate neuropathic pain and alleviate neuroinflammatory response in the spinal dorsal horn. J Pain Res. 2019;12:3221.","journal-title":"J Pain Res"},{"key":"152_CR208","doi-asserted-by":"crossref","unstructured":"Hada M. Chemotherapeutic Strategy with Synbiotics, Thalidomide and Celecoxib for severe COVID-19 Pneumonia. Association between microbiota, chronic inflammation and pneumonia. 2020.","DOI":"10.22541\/au.159188529.93357127"},{"key":"152_CR209","unstructured":"Chen C, et al. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 Pneumonia. 2020."},{"issue":"4","key":"152_CR210","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1097\/01.CCM.0000057900.19201.55","volume":"31","author":"BT Thompson","year":"2003","unstructured":"Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31(4):S253\u2013S257257.","journal-title":"Crit Care Med"},{"issue":"4","key":"152_CR211","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233.","journal-title":"Nat Rev Immunol"},{"issue":"16","key":"152_CR212","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711\u201323.","journal-title":"N Engl J Med"},{"key":"152_CR213","doi-asserted-by":"crossref","unstructured":"Wang Y, et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv. 2020.","DOI":"10.1101\/2020.03.06.20032342"},{"issue":"4","key":"152_CR214","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","volume":"31","author":"N Lee","year":"2004","unstructured":"Lee N, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304\u20139.","journal-title":"J Clin Virol"},{"issue":"6","key":"152_CR215","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","volume":"197","author":"YM Arabi","year":"2018","unstructured":"Arabi YM, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757\u201367.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10223","key":"152_CR216","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497\u2013506.","journal-title":"The Lancet"},{"key":"152_CR217","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tmaid.2019.03.004","volume":"29","author":"SH Alfaraj","year":"2019","unstructured":"Alfaraj SH, et al. Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study. Travel Med Infect Dis. 2019;29:48\u201350.","journal-title":"Travel Med Infect Dis"},{"issue":"21","key":"152_CR218","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1001\/jama.289.21.JOC30885","volume":"289","author":"CM Booth","year":"2003","unstructured":"Booth CM, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801\u20139.","journal-title":"JAMA"},{"issue":"1","key":"152_CR219","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jinf.2006.01.005","volume":"54","author":"LY-C Yam","year":"2007","unstructured":"Yam LY-C, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007;54(1):28\u201339.","journal-title":"J Infect"},{"issue":"2s","key":"152_CR220","first-page":"e43","volume":"4","author":"S Azimi","year":"2020","unstructured":"Azimi S, et al. Corticosteroids administration following COVID-19-induced acute respiratory distress syndrome. Is it harmful or life-saving? Adv J Emerg Med. 2020;4(2s):e43.","journal-title":"Adv J Emerg Med"},{"key":"152_CR221","doi-asserted-by":"crossref","unstructured":"Lewis SR, et al. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev. 2019; (7).","DOI":"10.1002\/14651858.CD004477.pub3"},{"key":"152_CR222","volume-title":"2019 novel coronavirus: an emerging global threat. In: Baylor University Medical Center Proceedings","author":"C Columbus","year":"2020","unstructured":"Columbus C, Brust KB, Arroliga AC. 2019 novel coronavirus: an emerging global threat. In: Baylor University Medical Center Proceedings. Milton Park: Taylor & Francis; 2020."},{"issue":"10223","key":"152_CR223","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","volume":"395","author":"CD Russell","year":"2020","unstructured":"Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395(10223):473\u20135.","journal-title":"The Lancet"},{"issue":"10225","key":"152_CR224","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","volume":"395","author":"L Shang","year":"2020","unstructured":"Shang L, et al. On the use of corticosteroids for 2019-nCoV pneumonia. The Lancet. 2020;395(10225):683\u20134.","journal-title":"The Lancet"},{"key":"152_CR225","unstructured":"WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020."},{"issue":"3","key":"152_CR226","first-page":"67","volume":"68","author":"WY Khot","year":"2020","unstructured":"Khot WY, Nadkar MY. The 2019 Novel Coronavirus outbreak\u2013a global threat. J Assoc Physicians India. 2020;68(3):67.","journal-title":"J Assoc Physicians India"},{"key":"152_CR227","doi-asserted-by":"crossref","unstructured":"Zhou Z-G, et al. Short-term moderate-dose corticosteroid plus immunoglobulin effectively reverses COVID-19 patients who have failed low-dose therapy. 2020.","DOI":"10.21203\/rs.3.rs-34078\/v1"},{"key":"152_CR228","doi-asserted-by":"crossref","unstructured":"Wu C, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med 2020","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"152_CR229","doi-asserted-by":"crossref","unstructured":"Horby PLW Emberson J, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. 2020.","DOI":"10.1101\/2020.06.22.20137273"},{"key":"152_CR230","doi-asserted-by":"crossref","unstructured":"Yuan H, et al. A current emerging respiratory infection: epidemiological and clinical characteristics, diagnosis and treatments of COVID-19. Diagnosis and treatments of COVID-19 (3\/6\/2020). 2020.","DOI":"10.2139\/ssrn.3551344"},{"key":"152_CR231","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-1-4684-5101-6_6","volume-title":"Steroid hormone resistance","author":"A Munck","year":"1986","unstructured":"Munck A, Guyre PM. Glucocorticoid physiology, pharmacology and stress. Steroid hormone resistance. Berlin: Springer; 1986. p. 81\u201396."},{"key":"152_CR232","unstructured":"Zhou Y-H, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J. 2020."},{"issue":"1","key":"152_CR233","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"W Zhou","year":"2020","unstructured":"Zhou W, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Trans Targeted Therapy. 2020;5(1):1\u20133.","journal-title":"Signal Trans Targeted Therapy"},{"key":"152_CR234","unstructured":"Sinha I. Guidance for the clinical management of children admitted to hospital with suspected COVID-19.\u00a0British Paediatric Respiratory Society. 2020."},{"key":"152_CR235","doi-asserted-by":"crossref","unstructured":"Matsuyama S, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020.","DOI":"10.1101\/2020.03.11.987016"},{"issue":"1","key":"152_CR236","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","volume":"26","author":"L Kaly","year":"2012","unstructured":"Kaly L, Rosner I. Tocilizumab\u2013A novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol. 2012;26(1):157\u201365.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"152_CR237","unstructured":"Zhang S, et al. Rational use of Tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Invest. 2020; p. 1\u20138."},{"issue":"7","key":"152_CR238","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang X, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307.","journal-title":"Blood Adv"},{"key":"152_CR239","doi-asserted-by":"crossref","unstructured":"De Luna G, et al. Rapid and severe Covid\u201019 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol. 2020.","DOI":"10.1002\/ajh.25833"},{"key":"152_CR240","doi-asserted-by":"crossref","unstructured":"Michot J-M, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020.","DOI":"10.1016\/j.annonc.2020.03.300"},{"key":"152_CR241","doi-asserted-by":"crossref","unstructured":"Coyle J, et al. A recovered case of COVID-19 myocarditis and ARDS treated with corticosteroids, tocilizumab, and experimental AT-001. JACC. 2020.","DOI":"10.1016\/j.jaccas.2020.04.025"},{"issue":"5","key":"152_CR242","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diii.2020.03.010","volume":"101","author":"M Cellina","year":"2020","unstructured":"Cellina M, et al. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn Interv Imaging. 2020;101(5):323\u20134.","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"152_CR243","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.chest.2020.04.024","volume":"158","author":"J Radbel","year":"2020","unstructured":"Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: a cautionary case report. Chest. 2020;158(1):e15\u20139.","journal-title":"Chest."},{"key":"152_CR244","unstructured":"Sciascia S, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19. Clin Exp Rheumatol. 2020; 8."},{"key":"152_CR245","first-page":"v1","volume":"202003","author":"X Xu","year":"2020","unstructured":"Xu X, et al. Effective treatment of severe COVID-19 patients with Tocilizumab. ChinaXiV. 2020;202003:v1.","journal-title":"ChinaXiV"},{"key":"152_CR246","doi-asserted-by":"crossref","unstructured":"Capra R, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020.","DOI":"10.1016\/j.ejim.2020.05.009"},{"key":"152_CR247","doi-asserted-by":"crossref","unstructured":"Rimland CA, et al. Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center. medRxiv. 2020.","DOI":"10.1101\/2020.05.13.20100404"},{"key":"152_CR248","doi-asserted-by":"crossref","unstructured":"Toniati P, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020; p. 102568.","DOI":"10.1016\/j.autrev.2020.102568"},{"key":"152_CR249","doi-asserted-by":"crossref","unstructured":"Vikse J, Henry BM. Tocilizumab in COVID-19: beware of risk of intestinal perforation. Int J Antimicrob Agents. 2020.","DOI":"10.1016\/j.ijantimicag.2020.106009"},{"key":"152_CR250","doi-asserted-by":"crossref","unstructured":"Mazzitelli M, et al. Use of subcutaneous tocilizumab in patients with COVID\u201019 pneumonia. J Med Virol. 2020.","DOI":"10.1002\/jmv.26016"},{"key":"152_CR251","unstructured":"https:\/\/www.nhc.gov.cn\/yzygj\/s7653p\/202003\/46c9294a7dfe4cef80dc7f5912eb1989\/files\/ce3e6945832a438eaae415350a8ce964.pdf. 2020."},{"issue":"1","key":"152_CR252","doi-asserted-by":"crossref","first-page":"e000930","DOI":"10.1136\/jitc-2020-000930","volume":"8","author":"FI Arnaldez","year":"2020","unstructured":"Arnaldez FI, O\u2019Day SJ, Drake CG, Fox BA, Fu B, Urba WJ, et al. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J immunother cancer. 2020;8(1):e000930.","journal-title":"J immunother cancer."},{"key":"152_CR253","doi-asserted-by":"crossref","unstructured":"Clerkin KJ, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020.","DOI":"10.1161\/CIRCULATIONAHA.120.046941"},{"key":"152_CR254","first-page":"1","volume":"3","author":"JP Guida","year":"2020","unstructured":"Guida JP. Chloroquine, Hydroxychloroquine and Covid-19: a systematic review of literature. Int Am J Med Health. 2020;3:1\u201310.","journal-title":"Int Am J Med Health"},{"key":"152_CR255","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.2147\/DDDT.S86438","volume":"9","author":"R Chen","year":"2015","unstructured":"Chen R, Chen B. Siltuximab (CNTO 328): a promising option for human malignancies. Drug Design Dev Ther. 2015;9:3455.","journal-title":"Drug Design Dev Ther"},{"issue":"10","key":"152_CR256","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-014-0249-x","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A, Patel T. Siltuximab: first global approval. Drugs. 2014;74(10):1147\u201352.","journal-title":"Drugs"},{"issue":"9","key":"152_CR257","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","volume":"15","author":"F Van Rhee","year":"2014","unstructured":"Van Rhee F, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966\u201374.","journal-title":"Lancet Oncol"},{"issue":"2","key":"152_CR258","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125\u201339.","journal-title":"Pharmacol Ther"},{"issue":"18","key":"152_CR259","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","volume":"17","author":"J Coward","year":"2011","unstructured":"Coward J, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011;17(18):6083\u201396.","journal-title":"Clin Cancer Res"},{"key":"152_CR260","unstructured":"Mart\u00ed\u2010Carvajal AJ, et al. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria. Cochrane Database Syst Rev (10)."},{"issue":"3","key":"152_CR261","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2125.2009.03491.x","volume":"68","author":"EA Dubois","year":"2009","unstructured":"Dubois EA, Cohen AF. Eculizumab. Br J Clin Pharmacol. 2009;68(3):318.","journal-title":"Br J Clin Pharmacol"},{"key":"152_CR262","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3947\/ic.2020.52.1.110","volume":"52","author":"YG Song","year":"2020","unstructured":"Song YG, Shin H-S. COVID-19, A clinical syndrome manifesting as hypersensitivity pneumonitis. Infect Chemother. 2020;52:110.","journal-title":"Infect Chemother"},{"key":"152_CR263","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.23.021704.115835","volume":"23","author":"R-F Guo","year":"2005","unstructured":"Guo R-F, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821\u201352.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"152_CR264","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","volume":"13","author":"G Struijk","year":"2013","unstructured":"Struijk G, et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant. 2013;13(3):819\u201320.","journal-title":"Am J Transplant"},{"issue":"7","key":"152_CR265","first-page":"4040","volume":"24","author":"F Diurno","year":"2020","unstructured":"Diurno F, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"152_CR266","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0378-8741(99)00141-5","volume":"69","author":"H-S Choi","year":"2000","unstructured":"Choi H-S, et al. Anti-inflammatory effects of fangchinoline and tetrandrine. J Ethnopharmacol. 2000;69(2):173\u20139.","journal-title":"J Ethnopharmacol"},{"issue":"12","key":"152_CR267","first-page":"1107","volume":"23","author":"Q-M Xie","year":"2002","unstructured":"Xie Q-M, et al. Pharmacological actions of tetrandrine in inflammatory pulmonary diseases. Acta Pharmacol Sin. 2002;23(12):1107\u201313.","journal-title":"Acta Pharmacol Sin"},{"key":"152_CR268","unstructured":"Chen S. Pathophysiology-based mechanism and management strategies for deadly leaking lungs caused by 2019 novel coronavirus."},{"key":"152_CR269","doi-asserted-by":"crossref","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020.","DOI":"10.1016\/S2213-2600(20)30116-8"},{"key":"152_CR270","doi-asserted-by":"crossref","unstructured":"Lei C, et al. Protocol of a randomized controlled trial testing inhaled Nitric Oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2). medRxiv. 2020.","DOI":"10.1101\/2020.03.09.20033530"},{"key":"152_CR271","doi-asserted-by":"crossref","unstructured":"De Luca D. Managing neonates with respiratory failure due to SARS-CoV-2. Lancet Child Adolescent Health. 2020.","DOI":"10.1016\/S2352-4642(20)30073-0"},{"key":"152_CR272","doi-asserted-by":"crossref","unstructured":"Gebistorf F, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev. 2016; (6).","DOI":"10.1002\/14651858.CD002787.pub3"},{"issue":"5","key":"152_CR273","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0196-0644(99)70167-8","volume":"34","author":"RO Wright","year":"1999","unstructured":"Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999;34(5):646\u201356.","journal-title":"Ann Emerg Med"},{"issue":"5","key":"152_CR274","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1213\/ANE.0b013e3181f46da8","volume":"111","author":"JR Feiner","year":"2010","unstructured":"Feiner JR, Bickler PE. Improved accuracy of methemoglobin detection by pulse CO-oximetry during hypoxia. Anesth Analg. 2010;111(5):1160\u20137.","journal-title":"Anesth Analg"},{"issue":"10","key":"152_CR275","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1086\/425357","volume":"39","author":"L Chen","year":"2004","unstructured":"Chen L, et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis. 2004;39(10):1531\u20135.","journal-title":"Clin Infect Dis"},{"key":"152_CR276","unstructured":"Berra L, et al. Protocol for a randomized controlled trial testing inhaled nitric oxide therapy in spontaneously breathing patients with COVID-19. medRxiv. 2020."},{"issue":"3","key":"152_CR277","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1183\/09031936.00056110","volume":"37","author":"RJ Barst","year":"2011","unstructured":"Barst RJ, et al. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J. 2011;37(3):665\u201377.","journal-title":"Eur Respir J"},{"issue":"1","key":"152_CR278","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1172\/JCI118386","volume":"97","author":"AH Cohen","year":"1996","unstructured":"Cohen AH, et al. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Investig. 1996;97(1):172\u20139.","journal-title":"J Clin Investig"},{"issue":"6","key":"152_CR279","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00345-019-02727-5","volume":"37","author":"C Duncan","year":"2019","unstructured":"Duncan C, et al. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol. 2019;37(6):1007\u2013144.","journal-title":"World J Urol"},{"issue":"5","key":"152_CR280","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1183\/09031936.00050008","volume":"32","author":"HH Leuchte","year":"2008","unstructured":"Leuchte HH, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008;32(5):1289\u201394.","journal-title":"Eur Respir J"},{"issue":"2","key":"152_CR281","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328\u201335.","journal-title":"Biochem Biophys Res Commun"},{"key":"152_CR282","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04355494, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04355494?term=NCT04355494&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR283","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04346797, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346797?term=NCT04346797&cond=COVID-19&draw=2&rank=1"},{"issue":"6","key":"152_CR284","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1017\/ice.2020.80","volume":"41","author":"M Zeinalian","year":"2020","unstructured":"Zeinalian M, et al. A potential protective role of losartan against coronavirus-induced lung damage. Infect Control Hosp Epidemiol. 2020;41(6):752\u20133.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"152_CR285","unstructured":"Wang Y, et al. Use of carrimycin in mycobacterium tuberculosis infection resistance. Google Patents."},{"issue":"4","key":"152_CR286","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/17476348.2020.1718495","volume":"14","author":"G Hillas","year":"2020","unstructured":"Hillas G, Fouka E, Papaioannou AI. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev Respir Med. 2020;14(4):353\u201365.","journal-title":"Expert Rev Respir Med"},{"issue":"10","key":"152_CR287","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-014-0249-x","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A, Patel T. Siltuximab: first global approval. Drugs. 2014;74(10):1147\u201352.","journal-title":"Drugs."},{"issue":"2","key":"152_CR288","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Therapeutics. 2014;141(2):125\u201339.","journal-title":"Pharmacol Therapeutics."},{"key":"152_CR289","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04280588, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04280588?term=NCT04280588&cond=COVID-19&draw=2&rank=1. 2020."},{"key":"152_CR290","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04305106, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04305106?term=NCT04305106&cond=COVID-19&draw=2&rank=1. 2020."},{"key":"152_CR291","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04275414, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04275414?term=NCT04275414&cond=COVID-19&draw=2&rank=1. 2020."},{"key":"152_CR292","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04329650, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04329650. 2020."},{"key":"152_CR293","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04377750, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04377750. 2020."},{"key":"152_CR294","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04377503, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04377503. 2020."},{"key":"152_CR295","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04321993, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04321993?term=NCT04321993&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR296","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04320277, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320277?term=NCT04320277&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR297","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04345289, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04345289?term=NCT04345289&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR298","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04268537, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04268537?term=NCT04268537&cond=COVID-19&draw=2&rank=1. 2020."},{"key":"152_CR299","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04366206, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04366206?term=NCT04366206&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR300","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04287686, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04287686?term=NCT04287686&cond=COVID-19&draw=2&rank=1.2020."},{"key":"152_CR301","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04264533, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04264533?term=NCT04264533&cond=COVID-19&draw=2&rank=1. 2020."},{"key":"152_CR302","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04323514, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04323514?term=NCT04323514&cond=COVID-19&draw=2&rank=1. 2020."},{"key":"152_CR303","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04310228, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04310228?term=NCT04310228&cond=COVID-19&draw=2&rank=1. 2020."},{"key":"152_CR304","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04319900, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04319900?term=NCT04319900&cond=COVID-19&draw=2&rank=1. 2020."},{"key":"152_CR305","unstructured":"Chinese Clinical Trial Register, Identifier: ChiCTR2000029600, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49042. 2020."},{"key":"152_CR306","unstructured":"Chen C, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv."},{"key":"152_CR307","unstructured":"Chinese Clinical Trial Register, Identifier: ChiCTR2000029544, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49013. 2020."},{"key":"152_CR308","unstructured":"Chinese Clinical Trial Register, Identifier: ChiCTR2000030113, Available From: www.chictr.org.cn\/hvshowproject.aspx?id=22695. 2020."},{"key":"152_CR309","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04273529, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273529?term=NCT04273529&draw=2&rank=1. 2020."},{"key":"152_CR310","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04312009, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04312009?term=NCT04312009&draw=2&rank=1. 2020."},{"key":"152_CR311","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04311177, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04311177. 2020."},{"key":"152_CR312","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04318418, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318418. 2020."},{"key":"152_CR313","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04261270, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261270?term=NCT04261270&draw=2&rank=1. 2020."},{"key":"152_CR314","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029387, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=48782. 2020."},{"key":"152_CR315","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029803, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49428. 2020."},{"key":"152_CR316","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029740, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49317. 2020."},{"key":"152_CR317","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029898, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49482. 2020."},{"key":"152_CR318","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029899, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49536. 2020."},{"key":"152_CR319","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030054, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49869. 2020."},{"key":"152_CR320","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029765, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49409. 2020."},{"key":"152_CR321","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030894, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=51126. 2020."},{"key":"152_CR322","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029542, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=48968. 2020."},{"key":"152_CR323","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030031, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49806. 2020."},{"key":"152_CR324","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000031204, Available From: www.chictr.org.cn\/hvshowproject.aspx?id=24756. 2020."},{"key":"152_CR325","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030718, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=50843. 2020."},{"key":"152_CR326","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030417, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=50279. 2020."},{"key":"152_CR327","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030987, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=48919. 2020."},{"key":"152_CR328","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029559, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=48880. 2020."},{"key":"152_CR329","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029609, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49145. 2020."},{"key":"152_CR330","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029741, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49263. 2020."},{"key":"152_CR331","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029760, Available From: www.chictr.org.cn\/hvshowproject.aspx?id=22820. 2020."},{"key":"152_CR332","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029761, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49400. 2020."},{"key":"152_CR333","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029762, Available From: www.chictr.org.cn\/hvshowproject.aspx?id=22816. 2020."},{"key":"152_CR334","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029826, Available From: www.chictr.org.cn\/hvshowproject.aspx?id=23666. 2020."},{"key":"152_CR335","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029837, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49495. 2020."},{"key":"152_CR336","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029868, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49524. 2020."},{"key":"152_CR337","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029935, Available From: https:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR2000029935. 2020."},{"key":"152_CR338","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029939, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49612. 2020."},{"key":"152_CR339","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029975, Available From: www.chictr.org.cn\/hvshowproject.aspx?id=22801. 2020."},{"key":"152_CR340","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029988, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49218. 2020."},{"key":"152_CR341","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029992, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49574. 2020."},{"key":"152_CR342","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04343768, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04343768. 2020."},{"key":"152_CR343","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04350671, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04350671. 2020."},{"key":"152_CR344","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04350281, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04350281. 2020."},{"key":"152_CR345","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04356677, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04356677. 2020."},{"key":"152_CR346","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04392427, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04392427. 2020."},{"key":"152_CR347","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04276688, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276688. 2020."},{"key":"152_CR348","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04323527, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04323527. 2020."},{"key":"152_CR349","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04261517, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261517. 2020."},{"key":"152_CR350","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04316377, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04316377. 2020."},{"key":"152_CR351","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04308668, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04308668. 2020."},{"key":"152_CR352","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04323631, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04323631. 2020."},{"key":"152_CR353","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04315896, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315896. 2020."},{"key":"152_CR354","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04318444, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318444. 2020."},{"key":"152_CR355","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04318015, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318015. 2020."},{"key":"152_CR356","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04303299, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04303299?term=NCT04303299&cond=COVID-19&draw=2&rank=1. 2020."},{"key":"152_CR357","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04303507, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04303507. 2020."},{"key":"152_CR358","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04322396, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322396. 2020."},{"key":"152_CR359","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04322123, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322123. 2020."},{"key":"152_CR360","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04321278, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04321278. 2020."},{"key":"152_CR361","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04315298, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315298. 2020."},{"key":"152_CR362","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04322773, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322773. 2020."},{"key":"152_CR363","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04317092, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04317092. 2020."},{"key":"152_CR364","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04315480, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315480. 2020."},{"key":"152_CR365","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04320615, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320615. 2020."},{"key":"152_CR366","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04306705, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04306705. 2020."},{"key":"152_CR367","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04313023, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04313023. 2020."},{"key":"152_CR368","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04312997, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04312997. 2020."},{"key":"152_CR369","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20100228003449N29, Available From: https:\/\/www.irct.ir\/trial\/46567. 2020."},{"key":"152_CR370","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20160625028622N1, Available From: https:\/\/www.irct.ir\/trial\/46576. 2020."},{"key":"152_CR371","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200128046294N2, Available From: https:\/\/www.irct.ir\/trial\/46463. 2020."},{"key":"152_CR372","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20100228003449N30, Available From: https:\/\/www.irct.ir\/trial\/46536. 2020."},{"key":"152_CR373","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04311697, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04311697. 2020."},{"key":"152_CR374","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04360096, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04360096. 2020."},{"key":"152_CR375","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04275245, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04275245. 2020."},{"key":"152_CR376","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04322682, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322682. 2020."},{"key":"152_CR377","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04322565, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322565. 2020."},{"key":"152_CR378","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04308317, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04308317. 2020."},{"key":"152_CR379","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04330638, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04330638. 2020."},{"key":"152_CR380","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04322188, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322188. 2020."},{"key":"152_CR381","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04321096, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04321096. 2020."},{"key":"152_CR382","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029308, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=48684. 2020."},{"key":"152_CR383","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029468, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=48919. 2020."},{"key":"152_CR384","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029539, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=48991. 2020."},{"key":"152_CR385","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029541, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=48992. 2020."},{"key":"152_CR386","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029548, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49015. 2020."},{"key":"152_CR387","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029603, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49075. 2020."},{"key":"152_CR388","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029621, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49165. 2020."},{"key":"152_CR389","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029638, Available From: www.chictr.org.cn\/hvshowproject.aspx?id=33516. 2020."},{"key":"152_CR390","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029656, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49086. 2020."},{"key":"152_CR391","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029759, Available From: https:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR2000029759. 2020."},{"key":"152_CR392","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000029989, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49720. 2020."},{"key":"152_CR393","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030013, Available From: https:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR2000030013. 2020."},{"key":"152_CR394","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030187, Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=50057. 2020."},{"key":"152_CR395","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030262 , Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=50136."},{"key":"152_CR396","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030442, Available From: https:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR2000030442. 2020."},{"key":"152_CR397","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030480 , Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=50470."},{"key":"152_CR398","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000031782 , Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=51934."},{"key":"152_CR399","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030481 , Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=50453."},{"key":"152_CR400","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000030922, Available From: www.chictr.org.cn\/hvshowproject.aspx?id=24034. 2020."},{"key":"152_CR401","unstructured":"Chinese Clinical Trial Register. Identifier: ChiCTR2000031196 , Available From: https:\/\/www.chictr.org.cn\/showprojen.aspx?proj=51112."},{"key":"152_CR402","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20151227025726N12, Available From: https:\/\/www.irct.ir\/trial\/46561. 2020."},{"key":"152_CR403","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04244591, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04244591. 2020."},{"key":"152_CR404","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04251871, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04251871. 2020."},{"key":"152_CR405","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04252274, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04252274?term=NCT04252274&draw=2&rank=1. 2020."},{"key":"152_CR406","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04254874, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04254874. 2020."},{"key":"152_CR407","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04255017, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04255017?term=NCT04255017&draw=2&rank=1. 2020."},{"key":"152_CR408","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04260594, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04260594. 2020."},{"key":"152_CR409","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04261426, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261426. 2020."},{"key":"152_CR410","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04261907, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261907. 2020."},{"key":"152_CR411","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04264858, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04264858. 2020."},{"key":"152_CR412","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04273581, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273581?term=NCT04273581&draw=2&rank=1. 2020."},{"key":"152_CR413","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04275388, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04275388. 2020."},{"key":"152_CR414","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04280705, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04280705. 2020."},{"key":"152_CR415","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04286503, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04286503. 2020."},{"key":"152_CR416","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04292730, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04292730. 2020."},{"key":"152_CR417","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04293887, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04293887. 2020."},{"key":"152_CR418","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04295551, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04295551. 2020."},{"key":"152_CR419","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04302766, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04302766. 2020."},{"key":"152_CR420","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04304053, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04304053?term=NCT04304053&draw=2&rank=1. 2020."},{"key":"152_CR421","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04304313, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04304313. 2020."},{"key":"152_CR422","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04305457, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04305457. 2020."},{"key":"152_CR423","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04306393, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04306393. 2020."},{"key":"152_CR424","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04307693, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04307693. 2020."},{"key":"152_CR425","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04312243, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04312243. 2020."},{"key":"152_CR426","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04320238, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320238. 2020."},{"key":"152_CR427","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04321174, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04321174. 2020."},{"key":"152_CR428","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04321616, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04321616. 2020."},{"key":"152_CR429","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04323592, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04323592. 2020."},{"key":"152_CR430","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04323761, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04323761. 2020."},{"key":"152_CR431","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04325633, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04325633. 2020."},{"key":"152_CR432","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04340050, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04340050. 2020."},{"key":"152_CR433","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04358614, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04358614. 2020."},{"key":"152_CR434","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04365764, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04365764?term=NCT04365764&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR435","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04273763, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273763?term=NCT04273763&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR436","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04355026, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04355026?term=NCT04355026&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR437","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04340349, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04340349?term=NCT04340349&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR438","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04345276, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04345276. 2020."},{"key":"152_CR439","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04346797, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346797. 2020."},{"key":"152_CR440","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04355494, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04355494. 2020."},{"key":"152_CR441","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04382950, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04382950?term=NCT04382950&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR442","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04363216, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04363216?term=NCT04363216&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR443","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04395768, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04395768?term=NCT04395768&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR444","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04342728, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04342728?term=NCT04342728&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR445","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04357782, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04357782?term=NCT04357782&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR446","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04344184, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04344184?term=NCT04344184&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR447","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT03680274, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03680274?term=NCT03680274&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR448","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200324046850N5, Available From: https:\/\/www.irct.ir\/trial\/46561."},{"key":"152_CR449","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200411047025N1, Available From: https:\/\/www.irct.ir\/trial\/47078. 2020."},{"key":"152_CR450","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04373044, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04373044?term=NCT04373044&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR451","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04340232, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04340232?term=NCT04340232&cond=COVID-19&draw=2&rank=1."},{"key":"152_CR452","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04393051, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04393051?term=NCT04393051&cond=COVID-19&draw=2&rank=1."},{"key":"152_CR453","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04362943, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04362943?term=NCT04362943&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR454","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04390464, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04390464?term=NCT04390464&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR455","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04346147, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346147?term=NCT04346147&cond=COVID-19&draw=2&rank=1"},{"key":"152_CR456","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04331470, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04331470. 2020."},{"key":"152_CR457","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04360122, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04360122. 2020."},{"key":"152_CR458","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04383717, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04383717. 2020."},{"key":"152_CR459","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04362332, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04362332. 2020."},{"key":"152_CR460","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04328493, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04328493. 2020."},{"key":"152_CR461","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04333628, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04333628. 2020."},{"key":"152_CR462","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04344951, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04344951. 2020."},{"key":"152_CR463","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04331600, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04331600. 2020."},{"key":"152_CR464","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04353336, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04353336. 2020."},{"key":"152_CR465","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04333732, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04333732. 2020."},{"key":"152_CR466","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04360759, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04360759. 2020."},{"key":"152_CR467","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04342650, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04342650. 2020."},{"key":"152_CR468","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04333914, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04333914. 2020."},{"key":"152_CR469","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04351191, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04351191. 2020."},{"key":"152_CR470","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04346667, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346667. 2020."},{"key":"152_CR471","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04349371, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04349371. 2020."},{"key":"152_CR472","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04341727, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04341727. 2020."},{"key":"152_CR473","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04359316, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359316. 2020."},{"key":"152_CR474","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04334148, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334148. 2020."},{"key":"152_CR475","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04324463, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04324463. 2020."},{"key":"152_CR476","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04342221, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04342221. 2020."},{"key":"152_CR477","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04351620, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04351620. 2020."},{"key":"152_CR478","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04385264, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04385264. 2020."},{"key":"152_CR479","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04329832, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04329832. 2020."},{"key":"152_CR480","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04334382, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334382. 2020."},{"key":"152_CR481","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04361318, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04361318. 2020."},{"key":"152_CR482","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04370782, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04370782. 2020."},{"key":"152_CR483","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04382625, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04382625. 2020."},{"key":"152_CR484","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04354597, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04354597. 2020."},{"key":"152_CR485","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04374903, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04374903. 2020."},{"key":"152_CR486","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04354441, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04354441. 2020."},{"key":"152_CR487","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04364815, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04364815. 2020."},{"key":"152_CR488","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04363866, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04363866. 2020."},{"key":"152_CR489","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04394442, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04394442. 2020."},{"key":"152_CR490","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04340544, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04340544. 2020."},{"key":"152_CR491","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04342156, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04342156. 2020."},{"key":"152_CR492","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04391127, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04391127. 2020."},{"key":"152_CR493","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04369742, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04369742. 2020."},{"key":"152_CR494","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04359953, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359953. 2020."},{"key":"152_CR495","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04371406, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04371406. 2020."},{"key":"152_CR496","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04329923, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04329923. 2020."},{"key":"152_CR497","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04357808, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04357808. 2020."},{"key":"152_CR498","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04386239, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04386239. 2020."},{"key":"152_CR499","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04357860, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04357860. 2020."},{"key":"152_CR500","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04327388, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04327388. 2020."},{"key":"152_CR501","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04324073, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04324073. 2020."},{"key":"152_CR502","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04332094, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04332094. 2020."},{"key":"152_CR503","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04332913, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04332913. 2020."},{"key":"152_CR504","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04377659, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04377659. 2020."},{"key":"152_CR505","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04331795, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04331795. 2020."},{"key":"152_CR506","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04345445, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04345445. 2020."},{"key":"152_CR507","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04359667, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359667. 2020."},{"key":"152_CR508","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04335071, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04335071. 2020."},{"key":"152_CR509","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04346355, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346355. 2020."},{"key":"152_CR510","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04372186, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04372186. 2020."},{"key":"152_CR511","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04363736, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04363736. 2020."},{"key":"152_CR512","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04361032, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04361032. 2020."},{"key":"152_CR513","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04363853, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04363853. 2020."},{"key":"152_CR514","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04356937, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04356937. 2020."},{"key":"152_CR515","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04370834, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04370834. 2020."},{"key":"152_CR516","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04403685, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04403685. 2020."},{"key":"152_CR517","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04331808, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04331808. 2020."},{"key":"152_CR518","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04361552, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04361552. 2020."},{"key":"152_CR519","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200324046850N2, Available From: https:\/\/www.irct.ir\/trial\/46713. 2020."},{"key":"152_CR520","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200325046859N1, Available From: https:\/\/www.irct.ir\/trial\/46811. 2020."},{"key":"152_CR521","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200328046886N1, Available From: https:\/\/www.irct.ir\/trial\/46885. 2020."},{"key":"152_CR522","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200418047126N1, Available From: https:\/\/www.irct.ir\/trial\/47707. 2020."},{"key":"152_CR523","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200421047155N1, Available From: https:\/\/www.irct.ir\/trial\/47387. 2020."},{"key":"152_CR524","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200422047168N1, Available From: https:\/\/en.irct.ir\/trial\/47437. 2020."},{"key":"152_CR525","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200325046859N2, Available From: https:\/\/www.irct.ir\/trial\/47200. 2020."},{"key":"152_CR526","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20190122042450N4, Available From: https:\/\/www.irct.ir\/trial\/47090. 2020."},{"key":"152_CR527","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20151222025660N2, Available From: https:\/\/www.irct.ir\/trial\/47319. 2020."},{"key":"152_CR528","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200406046968N1, Available From: https:\/\/www.irct.ir\/trial\/47021. 2020."},{"key":"152_CR529","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20151227025726N13, Available From: https:\/\/www.irct.ir\/trial\/46681. 2020."},{"key":"152_CR530","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200510047383N1, Available From: https:\/\/www.irct.ir\/trial\/48024. 2020."},{"key":"152_CR531","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20150303021315N17, Available From: https:\/\/www.irct.ir\/trial\/46550. 2020."},{"key":"152_CR532","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200511047396N1, Available From: https:\/\/www.irct.ir\/trial\/48048. 2020."},{"key":"152_CR533","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20190804044429N1, Available From: https:\/\/www.irct.ir\/trial\/46741. 2020."},{"key":"152_CR534","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20080901001165N53, Available From: https:\/\/www.irct.ir\/trial\/48066. 2020."},{"key":"152_CR535","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20100228003449N27, Available From: https:\/\/www.irct.ir\/trial\/46545. 2020."},{"key":"152_CR536","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20100228003449N28, Available From: https:\/\/www.irct.ir\/trial\/46538. 2020."},{"key":"152_CR537","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20150914024017N1, Available From: https:\/\/www.irct.ir\/trial\/46665. 2020."},{"key":"152_CR538","unstructured":"Iranian Clinical Trial Register. Identifier: IRCT20200406046968N3, Available From: https:\/\/www.irct.ir\/trial\/47152. 2020."},{"key":"152_CR539","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04348071, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04348071. 2020."},{"key":"152_CR540","unstructured":"ClinicalTrials.gov identifier (NCT number): NCT04381936, Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04381936?term=NCT04381936&cond=COVID-19&draw=2&rank=1. 2020."}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00152-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00152-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00152-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T05:36:20Z","timestamp":1667972180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00152-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":540,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00152-9","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"9 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest financial, academic, commercial, political or personal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of in interests"}},{"value":"Not applicable<b>.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}